54gene, Nigerian startup announces the launch of genomics research initiative

Nigerian startup 54gene, a pioneer in African genomics research, awareness, and development ment, has announced the launch of the African Centre for Translational Genomics(ACTG), an idea born of the pressing need to facilitate translational genomics research by African scientists.

About 54genehttp://<a href=”https://www.54gene.com”>54gene</a>
The first part of the name “54gene” is derived from the 54 countries making up Africa. The startup is the foremost in Affican genomics research for Africans and about Africans. It’s proudly set up to unlock the African genome by building the world’s first and largest Pan-African biobank. 54gene is trying to enhance personalized medicine for Africans and people of African origin and also to improve the quality of health care worldwide. The startup is very much committed to building genomics capability on the African continent and ensuring that its citizens are better-taken care of healthwise.

It is noteworthy that as of last year, 54gene has raised seed funding to the amount of US$4.5 million and has participated in several entrepreneurship programmes like Y Combinator and Google Launchpad Africa.

African Centre for Translational Genomics(ACTG)

ACTG is an initiative which according to 54gene is aimed at supporting and empowering the next generation of African genome scientists by offering them access to grants, fellowships, internships and training for medical researchers and students.

“In continuation with our belief at 54gene that genetic research in Africa should be ethical and beneficial to the communities we serve, and that African scientists be at the forefront of new drug discoveries that benefit Africans and the world at large, we have set up the ACTG to harness translational genetic research across Africa,” said 54gene founder Dr Abasi Ene-Obong.

The startup disclosed that the first study of ACTG will be funded by the Non – Communicable Diseases and Genetic Heritage Study Consortium(NCD – GHS).
Dr. Abasi Ene-Obong further commented, “The NCD-GHS study is our pilot effort under the ACTG that has the potential to rewrite the playbook of genomics research, where African scientists will be placed at the forefront of new drug discoveries for conditions that affect the health of not only Nigerians, but greater Africa and the world.”